Morningstar

Natera Inc NTRA

Stock XNAS Rating as of Oct 1, 2026

News

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Business Wire Sep 22, 2026, 12:00:00 PM
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

Business Wire Sep 18, 2026, 10:00:00 AM
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

Business Wire Sep 1, 2026, 10:00:00 AM
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Business Wire Aug 28, 2026, 3:03:00 PM
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

Business Wire Aug 27, 2026, 10:00:00 AM
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Business Wire Aug 12, 2026, 10:00:00 AM
Natera Reports Second Quarter 2026 Financial Results

Business Wire Aug 6, 2026, 8:05:00 PM
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Business Wire Aug 5, 2026, 10:00:00 AM
Natera to Report its Second Quarter Results on August 6, 2026

Business Wire Jul 30, 2026, 12:00:00 PM
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

Business Wire Jul 22, 2026, 10:00:00 AM
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio

Business Wire Jul 16, 2026, 10:35:00 PM
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Business Wire Jul 9, 2026, 10:00:00 AM
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

Business Wire Jul 6, 2026, 10:00:00 AM
Natera Gets FDA Approval for Bladder-Cancer Test

Global News Select May 15, 2026, 5:25:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.